메뉴 건너뛰기




Volumn 5, Issue 4, 2014, Pages 408-431

Emerging classes of armed antibody therapeutics against cancer

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BRENTUXIMAB VEDOTIN; CALICHEAMICIN; CAPECITABINE; CLIVATUZUMAB TETRAXETAN Y 90; CYTOTOXIC AGENT; DOXORUBICIN; FC RECEPTOR; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; GLEMBATUMUMAB VEDOTIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INOTUZUMAB OZOGAMICIN; INTERLEUKIN 12; INTERLEUKIN 2; ISOTOPE; LAPATINIB; MONOCLONAL ANTIBODY; RADIOISOTOPE; RADIUM CHLORIDE RA 223; RECOMBINANT INTERLEUKIN 2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TOSITUMOMAB I 131; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TUCOTUZUMAB CELMOLEUKIN; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

EID: 84896925253     PISSN: 20402503     EISSN: 20402511     Source Type: Journal    
DOI: 10.1039/c3md00360d     Document Type: Review
Times cited : (41)

References (250)
  • 183
    • 84896903556 scopus 로고    scopus 로고
    • Ph.D. thesis
    • M. D. Ruby and F. Meredith, Ph.D. thesis, 2011, http://clinicaltrials. gov/show/NCT01384253
    • (2011)
    • Ruby, M.D.1    Meredith, F.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.